Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US00534B1008
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01P202S42
ADGM
Adagio Medical Holdings Inc
GICS: - · SECTOR: EQTY · SUB-SECTOR: -
NAME
Adagio Medical Holdings Inc
ISIN
US00534B1008
TICKER
ADGM
MIC
XNAS
REUTERS
ADGM.OQ
BLOOMBERG
ADGM US
Sun, 26.04.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported six month results from its FULCRUM-VT Investigational Device Exemption (“IDE”) clinical trial, which will be used to support the Company’s application for Food and...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.04.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Ultra-low Temperature Ablation technologies (ULTA) for the treatment of scar-related ventricular tachycardia will be featured in several presentations at...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to expand the Company’s FULCRUM-VT trial to evaluate t...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating at the 25th Annual Needham Virtual Conference being held April 13-16, 2026. About Adagio Medical Holdings, Inc. Adagio is...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the pivotal results from the FULCRUM-VT study have been accepted for presentation in a late-breaking clinical science session at Heart Rhythm 2026 (HRS), the...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the fourth quarter ended December 31, 2025. Fourth Quarter and Recent Business Highlights: Announced the peer-reviewed publication in Ci...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of pre-clinical results of the Company’s next generation ultra-low temperature ablation (“ULTA”) technology designed to treat ventricular arrhythmi...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful completion of 13 ventricular ablation procedures at leading institutions using the Company’s proprietary Ultra-Low Temperature Ablation (ULTA) techn...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.03.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating in the 38th Annual Roth Conference on March 23-24, 2026 in Laguna Niguel, CA and will be hosting one-on-one meetings with inv...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.02.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA. Presentation Informat...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 04.02.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study (“EFS”) evaluating ultralow temperature cardiac ablation (“ULTC”) for the treatment of scar-related...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.02.2026       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 10, 2026...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.12.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced two key additions to its senior leadership team: Marie-Claude Jacques as Senior Vice President, Global Sales and Antwan Gipson as Senior Vice President, Manufactur...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that Sean Salmon has been appointed to its Board of Directors. Mr. Salmon will also serve on the Company’s Audit Committee and Compensation Committee. Mr. Salmon,...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross procee...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in N...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the closing of its previously announced private placement (https://investors.adagiomedical.com/news-releases/news-release-details/adagio-medical-announces-pricing-...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.10.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or the “Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with certain accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu t...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.10.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced preliminary acute (within 7 days) safety and efficacy results from the Adagio’s FULCRUM-VT Study evaluating Ultralow Temperature Cryoablation (“ULTC”) for the trea...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.10.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the completion of enrollment of the FULCRUM-VT Pivotal U.S. Food and Drug Administration (“FDA”) Investigational Device Exemption (“IDE”) study evaluating the Comp...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 18.09.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that acute results from the Company’s FULCRUM-VT U.S. pivotal study have been accepted for presentation in a late-breaking clinical science session at The 20th Ann...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.09.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the Company’s Chief Business Officer, Deborah Kaster’s, responsibilities have been expanded to include the role of Chief Financial Officer, effective Septembe...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.08.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Surpassed 85% enrollment in the FULCRUM-VT pivotal study of the Comp...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2025. Recent Business Highlights: Received Breakthrough Device Designation from the U.S. Food and Drug A...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities Health Care Conference on Tuesday, May 13, 2025, at 9:20 a.m. PT at the Encore Hotel in Las Vegas, NV. P...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.04.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that it has received Breakthrough Device designation from the U.S. Food and Drug Administration (“FDA”) for its vCLASTM Cryoablation System for the treatment of dr...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 31.03.2025       Adagio Medical
US00534B1008

Adagio Medical (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, is pleased to announce the appointment of Deborah Kaster as Chief Business Officer (CBO). Kaster brings more than 25 years of leadership experience in strategy, mergers and acquisitions, corporate finance, investor relations a...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 31.03.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Reported total company revenue of $137 thousand in the fourth quarter of 2024, co...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.03.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies, provided updates today on the progress in its streamlined focus on leadership in ventricular tachycardia (“VT”) solutions. Recent Business Highlights: The Company will participate in the scientific program of the 2025 European Hea...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Fri, 28.02.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced a corporate restructuring and realignment of resources to prioritize its FULCRUM-VT US pivotal investigational device exemption (“Pivotal IDE”) clinical trial activities and its ne...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.02.2025       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that management will be attending TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at the Marriott Copley Place in Boston, MA. About Adagio Medical Adagio...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.12.2024       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company” or “Adagio”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that founder Olav Bergheim departed as Chief Executive Officer (“CEO”) and Chairperson of the Board of Directors of the Company, effective December 13, 2024. Concurrent...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Thu, 14.11.2024       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company” or “Adagio”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced, today provided business updates for third quarter ended September 30, 2024. Recent Business Highlights: Reported total company revenue of $185 thousand in the thi...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.11.2024       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that its CEO & President, Olav Bergheim, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, at 9:45 a.m. Eastern Time in New York, NY at the Lotte Ne...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.10.2024       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; “Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies, today announced the completion of the first procedures in FULCRUM-VT U.S. Food and Drug Administration (FDA) Pivotal IDE study of Adagio’s VT Cryoablation System. Procedures were performed by Professor W...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 07.10.2024       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced its sponsorship and participation in the 19th Annual International Symposium on Ventricular Arrhythmias, to be held at the New York Marriott at the Brooklyn Bridge on October 11-12...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.08.2024       Adagio Medical
US00534B1008

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) sy...
Read more
Adagio Medical
Technical Analysis Termsheets Terminal
Permalink